HC Wainwright & Co. Maintains Neutral on Acelyrin, Lowers Price Target to $6

Benzinga · 01/07 11:24
HC Wainwright & Co. analyst Emily Bodnar maintains Acelyrin (NASDAQ:SLRN) with a Neutral and lowers the price target from $8 to $6.